HEMISPHERX BIOPHARMA, INC.
1617 JFK Boulevard
Philadelphia, Pennsylvania 19103
July 31, 2018
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20002
Re: | Hemispherx Biopharma, Inc. | ||
Registration Statement on Form S-3 | |||
(SEC filing No. 333-226059) | |||
Acceleration Request | |||
Requested Date: August 3, 2018 | |||
Requested Time: 4:00 P.M. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-226059) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.
Very truly yours, | ||
HEMISPHERX BIOPHARMA, INC. | ||
By: | /s/ Adam Pascale | |
Adam Pascale, | ||
Chief Financial Officer |
cc: Richard Feiner, Esq.